Novel p53 therapies for head and neck cancer
Inactivation of the tumor suppressor p53 is the predominant pathogenetic event in head and neck squamous cell carcinoma (HNSCC). The p53 pathway in HNSCC can be compromised through multiple mechanisms including gene mutations, hyperactivation of endogenous negative p53 regulators and by the human pa...
Guardado en:
Autores principales: | Mario R. Castellanos, Quintin Pan |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
KeAi Communications Co., Ltd.
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/7f96e30f0f9547dda9dba2c79df9c3a2 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Novel therapeutics and emerging technologies in head and neck cancer
por: Theodoros N. Teknos, M.D.
Publicado: (2016) -
The current status of oncolytic viral therapy for head and neck cancer
por: Matthew O. Old, et al.
Publicado: (2016) -
Circulating tumor cells in head and neck cancer: A review
por: Kyle P. McMullen, et al.
Publicado: (2016) -
The effect of treatment package time in head and neck cancer patients treated with adjuvant radiotherapy and concurrent systemic therapy
por: Ahmed I. Ghanem, et al.
Publicado: (2019) -
Intra-tumor heterogeneity in head and neck cancer and its clinical implications
por: Edmund A. Mroz, et al.
Publicado: (2016)